Abstract
Cystic fibrosis (CF) is the commonest autosomal recessive condition among Caucasian populations, affecting 1 in 2500 live births. The median age of survival has dramatically improved and will reach 40 years for children born in the 1990s. Complications such as cystic fibrosis related diabetes mellitus (CFRD) develop with age, and the median age at diagnosis is 21 years. The prevalence of CFRD progressively increases from 9% below the age of 10 years to 43% above the age of 30 years, with reported annual age-dependent incidence rates ranging from 4% to 9%. The onset of CFRD is insidious and annual screening using the standard oral glucose tolerance test (OGTT) from the age of 10 years has been recommended. However, OGTT thresholds for the diagnosis of impaired glucose tolerance and CFRD were derived from epidemiological studies of non-CF patients and it is uncertain whether they are appropriate for patients with CF. The ability of OGTT alone to detect early abnormalities in blood glucose regulation has been questioned. Continuous glucose monitoring systems (CGMS) may augment the screening and diagnosis of CFRD, as well as guide and monitor its management. Subcutaneous insulin therapy is currently recommended for the treatment of CFRD. Early use of insulin therapy might improve weight gain and lung function of CF patients, including those with normal OGTT results. It is still not clear when insulin therapy should be started, possibly reflecting the difficulties in detecting early but clinically relevant abnormalities in blood glucose metabolism among CF patients. We review the current evidence which highlight these diagnostic and management challenges in CFRD.
Keywords: Cystic fibrosis, Cystic fibrosis related diabetes, Impaired glucose tolerance, Oral glucose tolerance test, Continuous glucose monitoring systems
Current Diabetes Reviews
Title: Cystic Fibrosis Related Diabetes Mellitus - Diagnostic and Management Challenges
Volume: 6 Issue: 1
Author(s): Ngee Lek and Carlo L. Acerini
Affiliation:
Keywords: Cystic fibrosis, Cystic fibrosis related diabetes, Impaired glucose tolerance, Oral glucose tolerance test, Continuous glucose monitoring systems
Abstract: Cystic fibrosis (CF) is the commonest autosomal recessive condition among Caucasian populations, affecting 1 in 2500 live births. The median age of survival has dramatically improved and will reach 40 years for children born in the 1990s. Complications such as cystic fibrosis related diabetes mellitus (CFRD) develop with age, and the median age at diagnosis is 21 years. The prevalence of CFRD progressively increases from 9% below the age of 10 years to 43% above the age of 30 years, with reported annual age-dependent incidence rates ranging from 4% to 9%. The onset of CFRD is insidious and annual screening using the standard oral glucose tolerance test (OGTT) from the age of 10 years has been recommended. However, OGTT thresholds for the diagnosis of impaired glucose tolerance and CFRD were derived from epidemiological studies of non-CF patients and it is uncertain whether they are appropriate for patients with CF. The ability of OGTT alone to detect early abnormalities in blood glucose regulation has been questioned. Continuous glucose monitoring systems (CGMS) may augment the screening and diagnosis of CFRD, as well as guide and monitor its management. Subcutaneous insulin therapy is currently recommended for the treatment of CFRD. Early use of insulin therapy might improve weight gain and lung function of CF patients, including those with normal OGTT results. It is still not clear when insulin therapy should be started, possibly reflecting the difficulties in detecting early but clinically relevant abnormalities in blood glucose metabolism among CF patients. We review the current evidence which highlight these diagnostic and management challenges in CFRD.
Export Options
About this article
Cite this article as:
Lek Ngee and Acerini L. Carlo, Cystic Fibrosis Related Diabetes Mellitus - Diagnostic and Management Challenges, Current Diabetes Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339910790442600
DOI https://dx.doi.org/10.2174/157339910790442600 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Conformations and Assembly of Amyloid Oligomers by Electrospray Ionisation - Ion Mobility Spectrometry - Mass Spectrometry
Current Analytical Chemistry Islets From Rats and Pigs Transgenic for Photogenic Proteins
Current Diabetes Reviews Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Current Gene Therapy MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Current Neuropharmacology Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Ceruloplasmin, the Unique Multi-Copper Oxidase of Vertebrates
Protein & Peptide Letters Minimising the Effects of Isobaric Product Ions in SIFT-MS Quantification of Acetaldehyde, Dimethyl Sulphide and Carbon Dioxide
Current Analytical Chemistry Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders